Singapore markets open in 5 hours 8 minutes

Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
138.16+2.81 (+2.08%)
As of 03:52PM EDT. Market open.

Seagen Inc.

21823 30th Drive SE
Bothell, WA 98021
United States
425 527 4000
https://www.seagen.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees2,675

Key executives

NameTitlePayExercisedYear born
Dr. Roger D. Dansey M.D.Chief Medical Officer & Interim CEO1.53MN/A1956
Mr. Todd E. SimpsonChief Financial Officer1.17M13.84M1961
Ms. Jean I. Liu J.D., M.S.Chief Legal Officer1.11M8.23M1968
Mr. Charles R. RompExec. VP of Commercial U.S.1.02MN/A1968
Dr. Vaughn B. Himes Ph.D.Chief Technical OfficerN/AN/A1961
Peggy PinkstonSr. VP of Investor RelationsN/AN/AN/A
Mr. David CaouetteVP of Corp. CommunicationsN/AN/AN/A
Ms. Natasha A. HerndayExec. VP of Corp. Devel. & Alliance ManagementN/AN/A1972
Mr. Matt SkeltonVP of MarketingN/AN/AN/A
Mr. Christopher P. PawlowiczExec. VP of HRN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Corporate governance

Seagen Inc.’s ISS governance QualityScore as of 1 September 2022 is 4. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.